BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 745K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

18 articles for J Eksterowicz

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interaction.EBI
Amgen
Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.EBI
Amgen
Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interaction.EBI
Amgen
Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.EBI
Amgen
Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development.EBI
Amgen
Discovery and optimization of arylsulfonyl 3-(pyridin-2-yloxy)anilines as novel GPR119 agonists.EBI
Amgen
Inhibiting NF-¿B-inducing kinase (NIK): discovery, structure-based design, synthesis, structure-activity relationship, and co-crystal structures.EBI
Amgen
Analysis of kinase inhibitor selectivity using a thermodynamics-based partition index.EBI
Amgen
Orally Bioavailable Small-Molecule CD73 Inhibitor (OP-5244) Reverses Immunosuppression through Blockade of Adenosine Production.EBI
Oric Pharmaceuticals
Discovery of a Potent Steroidal Glucocorticoid Receptor Antagonist with Enhanced Selectivity against the Progesterone and Androgen Receptors (OP-3633).EBI
Oric Pharmaceuticals
Discovery of a Potent and Selective Steroidal Glucocorticoid Receptor Antagonist (ORIC-101).EBI
Oric Pharmaceuticals
Cyano-substituted heterocycles with activity as inhibitors of USP30BDB
Mission Therapeutics
Pyrimidine compounds as JAK kinase inhibitorsBDB
Theravance Biopharma R&D Ip
Pyridazinone macrocycles as IRAK inhibitors and uses thereofBDB
Merck Patent
Discovery of a Highly Selective STK16 Kinase Inhibitor.BDB
Chinese Academy of Sciences
Inhibition of arginine aminopeptidase by bestatin and arphamenine analogues. Evidence for a new mode of binding to aminopeptidases.BDB
University of Wisconsin
Application of fragment-based drug discovery to membrane proteins: identification of ligands of the integral membrane enzyme DsbB.BDB
Leiden University